Ovarian PRP: What It Is and Why It Remains Experimental
Key Takeaways
Ovarian PRP uses a concentrate from the patient's own blood, injected into the ovary. It is being studied for diminished ovarian reserve and poor response. Early studies report changes in some markers and occasional pregnancies, but the certainty of the evidence is low and PRP remains experimental, without proof that it improves live birth.
Key evidence: 2024 systematic review and meta-analysis of ovarian PRP in diminished reserve 2025 systematic review and meta-analysis in POI and poor response ASRM fertility evaluation guidance (2021)
What ovarian PRP is
Ovarian PRP uses a concentrate from the patient’s own blood, injected into the ovaries. It has attracted interest among people with diminished ovarian reserve or a poor response to ovarian stimulation. Interest is not the same as proof.
What it is trying to do
Platelets contain growth factors and other biologically active signals. Researchers hope that injecting them into the ovary may:
- influence local cell signalling,
- affect blood flow within the tissue,
- modify local inflammatory pathways,
- support the environment around existing follicles in selected patients.
These mechanisms are biologically plausible. They do not guarantee usable eggs, chromosomally normal embryos, or a live birth.
What human studies suggest so far
Some studies report changes after ovarian PRP in:
- AMH, FSH, or antral follicle count,
- the number of oocytes retrieved,
- embryo development,
- occasional pregnancies or live births.
The 2024 systematic review and meta-analysis of ovarian PRP in diminished ovarian reserve reported possible improvements in several fertility parameters, but the studies were heterogeneous and the authors noted that high-level evidence of effectiveness was still lacking (Éliás et al., 2024). A 2025 meta-analysis in premature ovarian insufficiency and poor ovarian response also reported changes in some ovarian-reserve and reproductive outcomes, while calling for further investigation (Sadeghpour et al., 2025).
Interpretation remains difficult because:
- many studies are small,
- preparation and injection protocols differ,
- patient selection varies substantially,
- control groups are often weak or absent,
- live-birth data are thinner than short-term hormone or ultrasound findings.
Taken together, the reviews suggest a possible signal, not a reliable treatment effect. The certainty of the evidence remains low.
Who asks about ovarian PRP most often
- diminished ovarian reserve,
- repeated poor response during IVF stimulation,
- premature ovarian insufficiency,
- disappointing cycles and interest in an additional experimental option.
The clinically important question is whether PRP changes the probability of obtaining usable eggs or a live birth compared with standard planning — not whether the idea sounds innovative.
Why it remains experimental
Important questions are still unsettled:
| Open question | Why it matters |
|---|---|
| How the concentrate is prepared | Results may not be comparable between clinics |
| Dose and injection technique | The ovaries, volume, and guidance method may differ |
| Who benefits | Age, AMH, and previous response are not the same across patients |
| How long any effect lasts | A temporary laboratory change is not a lasting fertility improvement |
| Placebo and cycle variation | Markers can fluctuate without PRP |
For these reasons, ovarian PRP should be discussed as an investigational procedure or an option supported by low-certainty evidence, not as routine fertility care.
How to weigh an ovarian PRP offer
If a clinic proposes ovarian PRP, ask for written answers before travelling or paying:
- Who is being selected, and how are age, AMH, and poor response defined?
- How is the concentrate prepared, and is the protocol published or independently audited?
- What outcome will be measured: hormone markers, eggs retrieved, embryos, pregnancy, or live birth?
- What is the follow-up window, and what happens if the markers do not change?
- How do the cost and delay compare with established IVF planning or a donor-egg discussion when age is already limiting?
An experimental option can be discussed honestly. It should not displace clearer decisions about timing, realistic egg expectations, or alternative paths. ASRM notes that fertility evaluation and indicated treatment may need to begin more promptly in people over 40; a delay should therefore be considered explicitly in the plan (ASRM, 2021).
Dr. Aksoy’s clinical note
The clinical question is not only whether a marker changes. Dr. Aksoy’s documented clinical point is that a temporary AMH rise or an additional follicle on ultrasound does not necessarily mean better egg chromosomal quality or a higher chance of live birth. Waiting three to six months for an unproven procedure may matter when reproductive reserve is declining with age.
Risks and practical issues
Using a person’s own blood reduces concerns about an immune reaction to donor material. The procedure is still invasive and may involve:
- pelvic discomfort,
- bleeding or infection,
- sedation or anaesthesia depending on the technique,
- cost without proven benefit,
- lost time when age already limits options.
For established paths, see how many eggs are usually enough for IVF? and egg-freezing planning. For another experimental ovarian approach, see exosomes and ovarian rejuvenation.
Related reading
- Exosomes for ovarian rejuvenation: still experimental
- How many eggs are usually enough for IVF?
- Egg freezing: age and numbers
FAQ
Is ovarian PRP a standard fertility treatment?
No. Protocols, patient selection, and live-birth evidence are not strong enough for routine care.
What changes have studies reported after PRP?
Some studies report changes in AMH, FSH, follicle count, oocytes, embryos, or pregnancies. Many of these findings come from small or weakly controlled studies, so they do not establish that PRP improves live birth.
What is the main risk of trying PRP?
Alongside procedural risks, the practical risk is spending time and money without proven benefit — especially when age is already limiting fertility options.
Who should be especially cautious?
People with age-limited fertility, very low reserve, or an urgent timeline should be cautious about delaying established options for an experimental step.
Sources
- Éliás M, et al. Platelet-rich plasma (PRP) treatment of the ovaries significantly improves fertility parameters and reproductive outcomes in diminished ovarian reserve patients: a systematic review and meta-analysis. Journal of Ovarian Research. 2024;17:104.
- Sadeghpour S, et al. Evaluation of intraovarian injection of platelet-rich plasma for enhanced ovarian function and reproductive success in women with POI and POR: a systematic review and meta-analysis. European Journal of Medical Research. 2025;30:610.
- Practice Committee of the American Society for Reproductive Medicine. Fertility evaluation of infertile women: a committee opinion. Fertility and Sterility. 2021;116(5):1255–1265.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.